title: Incidence of vitiligo in children with Graves' disease and Hashimoto's thyroiditis.
abstract: BACKGROUND
  Limited data are available on the association between vitiligo and autoimmune thyroid disease in pediatric patients. In addition, reported studies of pediatric patients have been based on a population known to have vitiligo and subsequently evaluated for the presence of thyroid function abnormalities.
  
  
  METHODS
  A retrospective chart review was performed on 333 children who had been followed for thyroid disorders by endocrinologists at the Yale Pediatric Thyroid Center over the last 5 years for autoimmune thyroid disease. Demographical and clinical features of patients found to have thyroid disease and vitiligo were recorded. These studies were approved by the Yale Human Investigation Committee.
  
  
  RESULTS
  Of the total 333 children and adolescents, 9 (2.7%) were noted to have vitiligo. Four patients (44%) had Graves' disease and 5 patients (66%) had Hashimoto's thyroiditis. For patients with Graves' disease and vitiligo, the average age of onset of thyroid disease was young at 4 ± 0.7 years, and the diagnosis of vitiligo usually preceded that of thyroid disease. For children with Hashimoto's thyroiditis and vitiligo, thyroid disease was diagnosed at an average age of 13.25 ± 2.8 years.
  
  
  CONCLUSIONS
  In our population, 4.6% of children with Graves' disease and 2.0% of children with Hashimoto's thyroiditis had vitiligo. Interestingly, when vitiligo presents with Graves' disease, it occurs in younger rather than older children.
authors.affiliation: Yale Pediatric Thyroid Center, Department of Pediatrics, Yale University, New Haven, CT, USA. scott.rivkees@yale.edu.
authors.forename: Brea
authors.initials: B
authors.lastname: Prindaville
authors.forename: Scott A
authors.initials: SA
authors.lastname: Rivkees
references.citation: J Am Acad Dermatol. 2010 Jun;62(6):945-9
references.pmid: 20466172
references.citation: J Eur Acad Dermatol Venereol. 2011 Jan;25(1):64-7
references.pmid: 20456552
references.citation: Pediatr Rev. 2009 Jul;30(7):251-8
references.pmid: 19570923
references.citation: Curr Opin Pediatr. 2010 Aug;22(4):445-52
references.pmid: 20616733
references.citation: Curr Opin Pediatr. 2009 Aug;21(4):523-8
references.pmid: 19474733
references.citation: Int J Dermatol. 2011 Feb;50(2):175-9
references.pmid: 21244381
references.citation: Pediatr Rev. 2004 Mar;25(3):94-100
references.pmid: 14993517
references.citation: N Engl J Med. 2007 Mar 22;356(12):1216-25
references.pmid: 17377159
references.citation: Pigment Cell Res. 2005 Aug;18(4):300-5
references.pmid: 16029422
references.citation: Curr Opin Rheumatol. 2007 Jan;19(1):44-8
references.pmid: 17143095
references.citation: J Am Acad Dermatol. 2005 Aug;53(2):220-3
references.pmid: 16021113
references.citation: Paediatr Drugs. 2003;5(2):95-102
references.pmid: 12529162
references.citation: Autoimmunity. 2001;34(1):65-77
references.pmid: 11681494
references.citation: J Clin Endocrinol Metab. 2002 Feb;87(2):489-99
references.pmid: 11836274
references.citation: J Pediatr Endocrinol Metab. 2001 Mar;14(3):229-43
references.pmid: 11308041
references.citation: World J Pediatr. 2009 Nov;5(4):265-8
references.pmid: 19911140
references.citation: Indian J Pediatr. 1997 Jan-Feb;64(1):3-10
references.pmid: 10771807
references.citation: Clin Endocrinol (Oxf). 2010 Mar;72(3):358-63
references.pmid: 19769613
references.citation: J Eur Acad Dermatol Venereol. 2004 Jan;18(1):109-11
references.pmid: 14678552
references.citation: Horm Res Paediatr. 2010;74(5):305-11
references.pmid: 20924158
references.citation: J Pediatr. 2006 Dec;149(6):827-32
references.pmid: 17137901